Cite
APA Citation
Riedel, R., Michels, S., Heydt, C., Siemanowski, J., Kobe, C., Bunck, A., Schäfer, S., Fischer, R. N., Scheffler, M., Abdulla, D. S., Nogová, L., Koleczko, S., Merkelbach-Bruse, S., Büttner, R., & Wolf, J. (2019). acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. Lung cancer, 133, 20–22. http://access.bl.uk/ark:/81055/vdc_100085410634.0x000050